Henan Lingrui Pharmaceutical Co Ltd (600285) - Total Liabilities
Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has total liabilities worth CN¥2.28 Billion CNY (≈ $333.69 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Henan Lingrui Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Henan Lingrui Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Henan Lingrui Pharmaceutical Co Ltd asset portfolio.
Henan Lingrui Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suning Commerce Group Co Ltd
SHE:002024
|
China | CN¥91.43 Billion |
|
Jiangsu Expressway Company Limited
F:JE2
|
Germany | €42.78 Billion |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
China | CN¥953.50 Million |
|
HBIS Resources Co Ltd
SHE:000923
|
China | CN¥4.35 Billion |
|
Siloam International Hospitals
JK:SILO
|
Indonesia | Rp5.29 Trillion |
|
Kernel Holding SA
WAR:KER
|
Poland | zł1.19 Billion |
|
Shinkong Insurance Co Ltd
TW:2850
|
Taiwan | NT$40.58 Billion |
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
India | Rs18.86 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Henan Lingrui Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Henan Lingrui Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Lingrui Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Lingrui Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total liabilities of Henan Lingrui Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $321.87 Million |
+13.58% |
| 2024-12-31 | CN¥1.94 Billion ≈ $283.38 Million |
-1.86% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.74 Million |
+10.49% |
| 2022-12-31 | CN¥1.79 Billion ≈ $261.34 Million |
+18.55% |
| 2021-12-31 | CN¥1.51 Billion ≈ $220.45 Million |
+32.66% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.17 Million |
+3.68% |
| 2019-12-31 | CN¥1.10 Billion ≈ $160.28 Million |
+7.86% |
| 2018-12-31 | CN¥1.02 Billion ≈ $148.60 Million |
-7.98% |
| 2017-12-31 | CN¥1.10 Billion ≈ $161.48 Million |
+26.94% |
| 2016-12-31 | CN¥869.35 Million ≈ $127.21 Million |
-11.70% |
| 2015-12-31 | CN¥984.58 Million ≈ $144.07 Million |
+7.76% |
| 2014-12-31 | CN¥913.70 Million ≈ $133.70 Million |
+37.76% |
| 2013-12-31 | CN¥663.24 Million ≈ $97.05 Million |
+11.03% |
| 2012-12-31 | CN¥597.36 Million ≈ $87.41 Million |
+14.00% |
| 2011-12-31 | CN¥524.02 Million ≈ $76.68 Million |
+7.11% |
| 2010-12-31 | CN¥489.25 Million ≈ $71.59 Million |
+29.25% |
| 2009-12-31 | CN¥378.52 Million ≈ $55.39 Million |
-9.56% |
| 2008-12-31 | CN¥418.55 Million ≈ $61.25 Million |
+15.21% |
| 2007-12-31 | CN¥363.31 Million ≈ $53.16 Million |
-7.33% |
| 2006-12-31 | CN¥392.03 Million ≈ $57.37 Million |
-0.10% |
| 2005-12-31 | CN¥392.44 Million ≈ $57.43 Million |
+9.21% |
| 2004-12-31 | CN¥359.36 Million ≈ $52.59 Million |
+24.07% |
| 2003-12-31 | CN¥289.65 Million ≈ $42.38 Million |
+3.08% |
| 2002-12-31 | CN¥281.00 Million ≈ $41.12 Million |
+77.19% |
| 2001-12-31 | CN¥158.59 Million ≈ $23.21 Million |
+49.15% |
| 2000-12-31 | CN¥106.33 Million ≈ $15.56 Million |
-5.85% |
| 1999-12-31 | CN¥112.94 Million ≈ $16.53 Million |
+49.04% |
| 1998-12-31 | CN¥75.78 Million ≈ $11.09 Million |
+36.02% |
| 1997-12-31 | CN¥55.71 Million ≈ $8.15 Million |
-- |
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more